Big Data, Real World, Multi-State Study Finds RSV Vaccine Highly Effective in Protecting Older Adults Against Severe Disease, Hospitalization and Death Oct. 17, 2024 — This multi-state study is ...
TORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
GlobalData on MSN4d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback